Prevention of thrombosis in hypercoagulable patients undergoing microsurgery: A novel anticoagulation protocol.
Research article published in Journal of plastic, reconstructive & aesthetic surgery : JPRAS (2016)
Abstract
BACKGROUND: Hypercoagulable conditions are often considered relative contraindications to free flap reconstruction. This paper presents and critically examines a novel anticoagulation regimen developed to address this disease state. METHODS: Hypercoagulable patients who underwent free tissue transfer between 2007 and 2015 were identified. From 2011, all such patients were subjected to a novel anticoagulation protocol involving an intravenous bolus of 2000 U of unfractionated heparin prior to microvascular pedicle anastomosis, followed by a heparin infusion at 500 U/h, which was postoperatively increased to therapeutic levels. Patients were discharged on full anticoagulation for 1 month. Patients prior to 2011 received only subcutaneous heparin. Outcomes in patients receiving this novel anticoagulation protocol were compared to those of patients receiving standard therapy (postoperative subcutaneous heparin). RESULTS: Twenty-three hypercoagulable patients underwent reconstruction with 32 flaps. Eleven patients were administered the novel protocol. No thromboses were noted in the novel protocol cohort, while three thrombotic events occurred in the control cohort (0% vs. 17.6%, p = 0.23). No flaps were salvaged after thrombosis. All losses occurred in the control cohort (0% vs. 17.6%, p = 0.23). The novel protocol cohort was more likely to have postoperative red blood cell transfusions (72.6% vs. 16.7%, p = 0.007), hematomas (26.7% vs. 0%, p = 0.04), and lower mean hemoglobin nadirs [6.9 (1.0) vs. 8.9 ± 1.8 g/dL, p = 0.01]. CONCLUSION: The key approach to hypercoagulable patients is likely prevention over treatment. Patients who received prophylactic heparin infusions had clinically lower rates of thrombotic events and flap loss. However, this encouraging finding must be balanced with the increased risk for postoperative bleeding complications.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Hypercoagulable conditions are often considered relative contraindications to free flap reconstruction. This paper presents and critically examines a novel anticoagulation regimen developed to address this disease state.
Por qué esto importa para la hirudoterapia
Este artículo examina un protocolo novedoso de anticoagulación sistémica que utiliza heparina no fraccionada por vía intravenosa para prevenir la trombosis en pacientes hipercoagulables sometidos a transferencia tisular libre (microcirugía). Si bien el protocolo novedoso mostró tasas más bajas de eventos trombóticos en comparación con la heparina subcutánea estándar, se asoció con riesgos significativamente mayores de complicaciones hemorrágicas, incluidos hematomas y transfusiones. Para la hirudoterapia, este estudio es clínicamente relevante porque la reconstrucción microvascular con colgajos libres es un escenario primordial donde se despliegan las sanguijuelas medicinales para salvar tejido con congestión venosa. Comprender los riesgos sistémicos de la anticoagulación quirúrgica aporta un marcado contraste con los efectos anticoagulantes localizados de la terapia con sanguijuelas. Sin embargo, este estudio no presenta relación directa con las sanguijuelas, ya que evalúa exclusivamente protocolos de heparina sistémica sin mencionar el secretoma de la sanguijuela ni la hirudoterapia.
Citación
Prevention of thrombosis in hypercoagulable patients undergoing microsurgery: A novel anticoagulation protocol.
Nelson et al. · Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2016
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026